InsidersTradesSigma
ZimVie Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the ZimVie Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ZimVie Inc. has logged 87 insider filings. The latest transaction was filed on 20 October 2025 (Disposition). Among the most active insiders: Jamali Vafa. Every trade is accessible without an account.
87
Insider Decl.
0
Thresholds
€1m
7 ops.
Buy Volume
€54m
14 ops.
Sell Volume
19Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 October 2025
Declarations87 total
40,794 sharesCommon StockSEC:0001193125-25-243795
125,389 sharesCommon StockSEC:0001193125-25-243767
63,438 sharesCommon StockSEC:0001193125-25-243829
40,127 sharesCommon StockSEC:0001193125-25-243820:0
83,674 sharesCommon StockSEC:0001193125-25-243713:0
389,152 sharesCommon StockSEC:0001193125-25-243730
40,127 sharesCommon StockSEC:0001193125-25-243820
83,674 sharesCommon StockSEC:0001193125-25-243713
63,438 sharesCommon StockSEC:0001193125-25-243829:0
389,152 sharesCommon StockSEC:0001193125-25-243730:0
125,389 sharesCommon StockSEC:0001193125-25-243767:0
40,794 sharesCommon StockSEC:0001193125-25-243795:0
11,127 shares0Common StockSEC:0001062993-25-009782:0
8,063 shares0Common StockSEC:0001062993-25-009780:0
10,966 shares0Common StockSEC:0001062993-25-009779:0
48,379 shares0Common StockSEC:0001062993-25-009778:0
16,127 shares0Common StockSEC:0001062993-25-009776:0
21,331 shares0Common StockSEC:0001062993-25-006967:0
90,065 shares0Common StockSEC:0001062993-25-006391:0
3,999 shares@ US$13.085.6% of flowCommon StockSEC:0001062993-25-006392:0
11,377 shares0Common StockSEC:0001062993-25-005150:0
90,065 shares0Common StockSEC:0001062993-25-005148:0
15,170 shares0Common StockSEC:0001062993-25-005149:0
24,650 shares0Common StockSEC:0001062993-25-005151:0
6,542 shares0Common StockSEC:0001062993-25-005152:0
25 of 87 declarations
About ZimVie Inc.
ZimVie Inc. is a U.S.-based medical device company that was listed on the Nasdaq in the United States. The company was formed in March 2022 as an independent public spin-off from Zimmer Biomet, bringing together the former Dental and Spine businesses under a standalone structure. ZimVie is headquartered in Palm Beach Gardens, Florida, and has historically served customers in more than 70 countries through a global commercial footprint and additional facilities around the world. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-report-fourth-quarter-and-full-year-2024-financial/?utm_source=openai)) In terms of business lines, ZimVie has been best known for dental implantology and restorative dentistry solutions. Its portfolio includes dental implants, prosthetic components, healing abutments, biomaterials, and digital workflow solutions used by dental professionals, implant surgeons, labs, and distributors. The company’s products are positioned around tooth replacement and restoration procedures, with a strong emphasis on clinically supported, differentiated platforms. ZimVie also had a spine business in its early post-spin-off years, but that segment was sold and closed in April 2024, leaving the company more tightly focused on dental. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-report-fourth-quarter-and-full-year-2024-financial/?utm_source=openai)) From a competitive standpoint, ZimVie operates as a specialized player in a global market that is populated by large, well-capitalized competitors. Its investment case has therefore centered on product differentiation, clinical evidence, international distribution, and portfolio focus rather than scale alone. After the spine divestiture, management emphasized a leaner structure and greater concentration of capital and attention on the dental franchise. That strategic reset is important for equity investors because it makes ZimVie a more focused dental company than the broader musculoskeletal and dental platform it once was. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-announces-closing-sale-spine-business?utm_source=openai)) Recent corporate news was especially significant. In July 2025, ZimVie announced a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash. In October 2025, stockholders approved the transaction, and ZimVie later announced that the acquisition had been completed, after which the company became privately held. For market participants tracking ZIMV on the Nasdaq, this was the defining event of the period and materially changed the company’s public-market status, ownership structure, and strategic outlook. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-announces-definitive-agreement-be-acquired-archimed-1900?utm_source=openai))
